Health care shares moved higher on Tuesday as investors continued shifting money into defensive corners of the market, according to Morningstar. Insurers extended recent gains, and several individual drug developers drew attention on company-specific news.
UnitedHealth Group and Humana both added to advances built up over recent weeks. Morningstar reported that UnitedHealth has gained 13% over the past month.
The sector's strength stood out against a broader market that was also rising. MarketWatch reported that health care rallied to a record high even as the wider market posted gains of its own. Axios and EBC Financial Group also covered the sector's rally, with EBC framing the question around why health care stocks were reaching record levels in October 2026.
Why it matters
Health care is traditionally treated as a defensive sector, meaning its companies are seen as holding up relatively well when investors grow cautious about the economic outlook. When money rotates into these names, it can signal that portfolio managers are looking for stability rather than chasing risk.
The move is notable because it came alongside gains in the broad market rather than in place of them. That suggests health care was attracting fresh money rather than simply benefiting from a selloff elsewhere. MarketWatch's description of a record high for the sector underlines how strong the run has been.
For investors, the rotation matters because it can reshape which parts of the market lead and which lag. Insurers, which sit close to the center of the health care system, are often among the first names to move when sentiment toward the sector shifts.
Insurers extend their run
The insurance side of the sector carried much of the momentum. UnitedHealth and Humana were both cited by Morningstar as adding to recent gains, with UnitedHealth's 13% rise over the past month offered as a measure of how far the stock has come.
Morningstar's report did not attribute the rotation to a single cause, describing it instead as a continued move toward defensive companies. That framing places the day's trading in the context of a broader preference for stability rather than a reaction to one specific event.
AstraZeneca pairs with Oracle on AI research
Among individual companies, AstraZeneca drew notice after saying it would work with Oracle to sharpen its clinical research, according to Morningstar. The British drugmaker's partnership is the latest example of artificial intelligence being brought into pharmaceutical development.
The announcement fits a wider pattern of drug companies turning to technology firms for help with the data-heavy work that underpins trials and research. Morningstar did not disclose financial terms or a timeline for the collaboration.
Rapport Therapeutics gains on trial results
Rapport Therapeutics also moved higher after its experimental treatment performed well in a mid-stage study involving bipolar patients in a manic episode, Morningstar reported. The result gave the drug developer a positive clinical readout, a type of news that can move small biotech shares sharply.
Yahoo Finance, in a roundup of individual movers, listed Moderna, Progyny, Azenta, Oscar Health and agilon health among the companies whose shares jumped. The outlet did not, in the material available, tie each of those moves to a specific cause.
Morningstar noted that some of the content on its page was supplied by third parties and that it does not endorse, review or verify such material. The outlet also stated that it makes no guarantees about the accuracy, completeness or timeliness of third-party content and that readers should seek independent financial advice before acting on it.
What to watch next: whether the defensive rotation holds through the coming sessions, and how the sector reacts as more companies report trial data and partnership news.
